# A Study of YL242 in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07197827/  
OnCo record `nct07197827` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL242 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07197827 by MediLink Therapeutics (Suzhou) Co., Ltd., with 424 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-09. Interventions recorded: YL242, YL242; Pembrolizumab, YL242; 5-FU; LV and YL242; Pembrolizumab; 5-FU.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07197827
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 424

## Sources

- ClinicalTrials.gov NCT07197827: https://clinicaltrials.gov/study/NCT07197827

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07197827.json